Procainamide and quinidine inhibition of the human hepatic degradation of meperidine in vitro.
Procainamide and quinidine inhibition of the degradation of meperidine in human liver was investigated by incubation of two concentrations of either drug with meperidine in homogenates of human liver over 24 and 36 h. Meperidine concentrations declined by 26% after incubation for 24 h and by 42% after incubation for 36 h. In the presence of procainamide, however, they decreased by only 15% to 18% at 24 h and by only 26% to 28% at 36 h. In the presence of quinidine, they declined by only 18% to 19% at 24 h and by only 27% to 28% at 36 h. Procainamide and quinidine may inhibit human hepatic carboxylesterase hCE-1, which is responsible for catalyzing the hydrolysis of meperidine. This inhibition may prolong the biological half-life of meperidine in patients receiving the drug together with either procainamide or quinidine.
Division of Laboratory Medicine, Department of Pathology, University of California, San Diego Medical Center, 200 West Arbor Drive, San Diego, California 92103-8320, USA. dnbailey@ucsd.edu
David N
DN
Bailey
John R
JR
Briggs
D002849:Chromatography, Gas; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D008614:Meperidine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009294:Narcotics / Q000378:metabolism*; D011342:Procainamide / Q000494:pharmacology*; D011802:Quinidine / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D009294:Narcotics; D008614:Meperidine; D011802:Quinidine; D011342:Procainamide